Company NeuroSense Therapeutics Ltd.

Equities

NRSN

IL0011809592

Biotechnology & Medical Research

Analysts' Consensus

Business Summary

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Bio Therapeutic Drugs

Market Closed - Nasdaq Other stock markets 21:30:01 10/05/2024 BST			5-day change	1st Jan Change
1.18 ^USD	+0.53%		-11.28%	+50.32%

05-07	NeuroSense Announces New Positive Data Analysis from PARADIGM Clinical Trial Demonstrating Statistically Significant Slowing of Disease Progression in High-Risk ALS Patients	CI
04-22	NeuroSense to Collaborate With Genetika+ on Alzheimer's Disease Drug Development; Shares Fall	MT

NeuroSense Therapeutics Ltd is an Israel-based clinical-stage pharmaceutical company. The Company is active in field of drug development and treatment offers Amyotrophic Lateral Sclerosis (ALS) patients, as well as other neurodegenerative diseases. The Company's lead product candidate, PrimeC, is an oral formulation of a fixed dose combination composed of a specific ratio of drugs. In addition to PrimeC, the Company has initiated research and development efforts in Alzheimer's disease and Parkinson's disease

Number of employees: 18

Managers	Title	Age	Since
Alon Ben-Noon FOU	Founder	45	12/02/17
Or Eisenberg DFI	Director of Finance/CFO	43	31/05/21
Hagit Binder COO	Chief Operating Officer	-	-
Shiran Zimri CTO	Chief Tech/Sci/R&D Officer	-	31/01/20
Irit Shefer CTO	Chief Tech/Sci/R&D Officer	-	31/01/22
Ferenc Tracik CTO	Chief Tech/Sci/R&D Officer	60	30/11/21
Oron Yacoby-Zeevi CTO	Chief Tech/Sci/R&D Officer	63	-
Diana Shtossel LAW	General Counsel	-	31/12/21
Nedira Salzman-Frenkel. PRN	Corporate Officer/Principal	-	28/02/22

Members of the board	Title	Age	Since
Christine Pellizzari BRD	Director/Board Member	56	20/12/21
Mark Leuchtenberger CHM	Chairman	67	30/09/21
Cary Claiborne BRD	Director/Board Member	64	30/11/21
Revital Mandil–Levin BRD	Director/Board Member	49	31/12/21
Caren Deardorf BRD	Director/Board Member	59	20/12/21
Alon Ben-Noon FOU	Founder	45	12/02/17

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	17,334,042	12,382,922 ( 71.44 %)	0	71.44 %

Name	Equities	%	Valuation
Alon Ben-Noon 22.35 %	3,054,600	22.35 %	6 M $
Ariel Gordon 7.571 %	1,034,607	7.571 %	2 M $
Or Eisenberg 3.366 %	460,008	3.366 %	837 215 $
Ferenc Tracik 0.8997 %	122,951	0.8997 %	223 771 $
Niva Russek Blum 0.4788 %	65,428	0.4788 %	119 079 $
Mark Leuchtenberger 0.4683 %	64,000	0.4683 %	116 480 $
MEITAV INVESTMENT HOUSE LTD 0.3659 %	50,000	0.3659 %	91 000 $
Revital Mandil–Levin 0.2087 %	28,526	0.2087 %	51 917 $
Christine Pellizzari 0.1756 %	24,000	0.1756 %	43 680 $
Cary Claiborne 0.1756 %	24,000	0.1756 %	43 680 $

Name	Equities	%	Valuation
Hudson Bay Capital Management LP -	86,753	-	36 436 $
Clear Street LLC -	59,272	-	24 894 $
Warberg Asset Management LLC -	41,406	-	17 391 $

Neurosense Therapeutics Ltd.

11 HaMenofim Street Building B

46725, Herzliya

http://www.neurosense-tx.com

address NeuroSense Therapeutics Ltd.(NRSN)

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

1.174 USD

Average target price

5.25 USD

Spread / Average Target

+347.27%

Consensus

Estimates Revisions

Company calendar

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Bio Therapeutic Drugs

	1st Jan change	Capi.
NEUROSENSE THERAPEUTICS LTD.	+50.32%	20.35M
VERTEX PHARMACEUTICALS INCORPORATED	+3.91%	108B
REGENERON PHARMACEUTICALS, INC.	+10.87%	104B
ARGENX SE	+1.28%	22.33B
BIONTECH SE	-13.14%	22.19B
GENMAB A/S	-7.05%	18.69B
WUXI APPTEC CO., LTD.	-38.36%	17.74B
BEIGENE, LTD.	-10.66%	17.64B
NEUROCRINE BIOSCIENCES, INC.	+3.75%	14.05B
SAREPTA THERAPEUTICS, INC.	+36.70%	12.51B

Bio Therapeutic Drugs